The Lipid Accumulation Product Is Associated with Impaired Glucose Tolerance in PCOS Women

Wehr, Elisabeth; Gruber, Hans-Jürgen; Giuliani, Albrecht; Möller, Reinhard; Pieber, Thomas R.; Obermayer–Pietsch, Barbara

doi:10.1210/jc.2011-0031

Cited by 71 publications

(80 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This notion is supported by our finding showing a strong correlation of VAT and trunk located fat layers with FLI, whereas leg fat layers were inversely correlated with FLI. Of note, high levels of lipid accumulation product reflecting increased abdominal fat deposition are higher in PCOS than in BMI-matched control women and have been linked to IGT in PCOS women (32). Interestingly, PCOS women with a fatty liver have increased preperitoneal, mesenteric, and subcutaneous fat as well as an increased intima-media thickness (33), which is in line with our data showing a correlation of FLI with an adverse metabolic profile.…”

Section: Discussionsupporting

confidence: 89%

Fatty liver index in polycystic ovary syndrome

Lerchbaum¹,

Gruber²,

Schwetz³

et al. 2011

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Introduction: Women with polycystic ovary syndrome (PCOS) frequently suffer from metabolic disturbances and might be affected by hepatic steatosis. The fatty liver index (FLI) was developed as a simple and accurate predictor of hepatic steatosis. We aimed to analyze the association of FLI with endocrine and metabolic parameters in a cohort of PCOS and control women. Methods: FLI was calculated using body mass index (BMI), waist circumference, triglycerides, and gamma-glutamyl transferase in 611 PCOS and 139 BMI-matched control women within the same age range. Elevated FLI was defined as O60. Metabolic, endocrine, and anthropometric measurements and oral glucose tolerance tests were performed. Results: PCOS women had significantly higher FLI levels than control women in age-adjusted analyses (11.4 (4.3-48.8) and 8.8 (3.9-35.0), respectively, PZ0.001), whereas fibrosis indices were similar (aspartate amino transferase-to-platelet ratio index) or lower (FIB-4) respectively. In binary logistic regression analysis adjusted for age, odds ratio (OR) for elevated FLI was 2.52 (1.31-4.85), PZ0.006, for PCOS women when compared with controls. PCOS women with high FLI levels had an adverse anthropometric, metabolic, and endocrine risk profile. The prevalence of elevated FLI was 88.7% in PCOS women with metabolic syndrome (MS) and 11.3% in PCOS women without MS (P!0.001). In control women, elevated FLI was present in 66.7% of women with MS and 30.8% of women without MS. Conclusion: High FLI levels are a common finding in obese PCOS women and are closely linked to MS. FLI calculation might be a useful tool for identifying PCOS patients at high risk for metabolic and hepatic disturbances.

show abstract

Section: Discussionsupporting

confidence: 89%

Fatty liver index in polycystic ovary syndrome

Lerchbaum¹,

Gruber²,

Schwetz³

et al. 2011

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…(triglycerides (TG) (mmol/l)). Elevated LAP was defined as O44.1 as described previously in a large PCOS cohort as best cut-off for detecting disturbed glucose tolerance (8). VAI was calculated using the formula ðWC ðcmÞ=ð36:58…”

Section: Methodsmentioning

confidence: 99%

“…This notion is supported by a study among 469 South Asian PCOS women with increasing MS prevalence from the lowest (6.7%) to highest (42.0%) quartiles of BMI and a relatively high overall prevalence of 36%. Further, central obesity and visceral fat accumulation have been associated as key factors in the development of the MS, and the prevalence of the MS is low if there is no excessive abdominal adiposity (8,9). Moreover, non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of MS and it has been shown that 89% of PCOS women with MS have elevated fatty liver index indicating NAFLD (24).…”

Section: European Journal Of Endocrinologymentioning

confidence: 99%

“…PCOS women present not only with hyperandrogenism but also affected by an increased metabolic risk which might be related to obesity as well as to genetic and environmental factors (6). There is accumulating evidence suggesting that central obesity is the key factor in the development of metabolic and cardiovascular risk in PCOS women (7,8,9). In this context, several indices such as lipid accumulation product (LAP) (8,10) and visceral adiposity index (VAI) (11) have been shown to be associated with an increased risk of insulin resistance, prediabetes and type 2 diabetes mellitus (T2DM) in PCOS as well as in other cohorts.…”

Section: Introductionmentioning

confidence: 99%

“…There is accumulating evidence suggesting that central obesity is the key factor in the development of metabolic and cardiovascular risk in PCOS women (7,8,9). In this context, several indices such as lipid accumulation product (LAP) (8,10) and visceral adiposity index (VAI) (11) have been shown to be associated with an increased risk of insulin resistance, prediabetes and type 2 diabetes mellitus (T2DM) in PCOS as well as in other cohorts. Further, there is evidence showing that a positive family history (FHx) of T2DM, as a reflection of genetic risk, is associated with an increased risk of the development of T2DM in PCOS women (12,13,14).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women

Lerchbaum

Schwetz

Obermayer-Pietsch

2014

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective: There is evidence suggesting a strong genetic background of polycystic ovary syndrome (PCOS). We aim to study the metabolic and endocrine characteristics of PCOS women with and without a family history (FHx) of type 2 diabetes mellitus (T2DM) and PCOS. Design: Cross-sectional study. Methods: We analysed the association of T2DM FHx and PCOS FHx with metabolic and endocrine parameters in 714 PCOS women. Results: A positive FHx of T2DM and PCOS were prevalent in 36.8 and 21.4% of PCOS women respectively. We found an independent association of T2DM FHx with central fat accumulation, obesity, prediabetes, metabolic syndrome (MS), insulin resistance, low HDL and elevated blood pressure (P!0.05 for all). PCOS FHx was independently associated with prediabetes (P!0.05). We observed an independent association of PCOS FHx with clinical and biochemical hyperandrogenism (P!0.05 for all), whereas there was no independent association of T2DM FHx with hyperandrogenism. PCOS women with a positive FHx of both T2DM and PCOS had an adverse metabolic and endocrine profile including a linear increase in risk of obesity, central fat accumulation, MS, prediabetes and low HDL (P!0.05 for all). Conclusions: Our findings suggest that the assessment of FHx might allow risk stratification of PCOS women, which is important considering the high prevalence of PCOS.

show abstract

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

et al. 2016

View full text Add to dashboard Cite

The Lipid Accumulation Product Is Associated with Impaired Glucose Tolerance in PCOS Women

Abstract: LAP is an easily obtainable and cheap marker associated with IGT in PCOS and control women.

Cited by 71 publications

References 20 publications

Fatty liver index in polycystic ovary syndrome

Fatty liver index in polycystic ovary syndrome

Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Contact Info

Product

Resources

About